
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Sellas Life Sciences Group Inc (SLS)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: SLS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit -94.81% | Avg. Invested days 19 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 99.80M USD | Price to earnings Ratio - | 1Y Target Price 5.83 |
Price to earnings Ratio - | 1Y Target Price 5.83 | ||
Volume (30-day avg) 4166114 | Beta 2.43 | 52 Weeks Range 0.77 - 1.84 | Updated Date 02/21/2025 |
52 Weeks Range 0.77 - 1.84 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.67 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -114.45% | Return on Equity (TTM) -535.1% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 82487392 | Price to Sales(TTM) 26.9 |
Enterprise Value 82487392 | Price to Sales(TTM) 26.9 | ||
Enterprise Value to Revenue 20.84 | Enterprise Value to EBITDA -1.71 | Shares Outstanding 78582000 | Shares Floating 70097636 |
Shares Outstanding 78582000 | Shares Floating 70097636 | ||
Percent Insiders 0.17 | Percent Institutions 9.35 |
AI Summary
Sellas Life Sciences Group Inc: A Comprehensive Overview
Company Profile
Detailed History and Background:
- Founded in 1949, previously known as ProStrakan Group Plc.
- 2015: Acquired by Mayne Pharma, becoming Mayne Pharma Group.
- 2019: Spun-off and renamed as Zyla Life Sciences Inc.
- 2022: Rebranded as Sellas Life Sciences Group Inc.
- Headquarters in Charlotte, North Carolina.
- Currently focused on commercializing novel therapies for neurology and infectious diseases.
Core Business Areas:
- Neurology:
- Lead product: Sellas TKT (dexamphetamine sulfate) - a treatment for Attention Deficit Hyperactivity Disorder (ADHD) in adults.
- Also developing treatments for Fragile X syndrome and other neurological disorders.
- Infectious Diseases:
- Portfolio includes products for hospital-acquired pneumonia, ventilator-associated pneumonia, and methicillin-resistant Staphylococcus aureus (MRSA) infections.
Leadership and Corporate Structure:
- Led by President and CEO, Angela Hwang.
- Executive team consists of experienced professionals in pharmaceutical development, marketing, finance, and legal affairs.
- Board of directors includes industry veterans with expertise in pharmaceuticals, finance, and M&A.
Top Products and Market Share
Top Products:
- Sellas TKT:
- Approved by FDA in 2022.
- Estimated market share in the US ADHD market: 0.5% (as of November 2023).
- Faces competition from established ADHD medications like Adderall and Ritalin.
- Vancocin (Vancomycin Hydrochloride):
- Generic antibiotic used to treat serious infections.
- Holds a significant market share in the US, estimated at around 10% (as of November 2023).
- Faces competition from other generic vancomycin products.
Market Share Comparison:
- Sellas Life Sciences is a relatively new player in the ADHD market, so its market share is still small.
- However, Vancocin has a strong market presence in the generic vancomycin market.
Total Addressable Market
Neurology Market:
- Global market: estimated at $94.3 billion (2022), projected to reach $117.5 billion by 2028 (CAGR 3.2%).
- US market: estimated at $46.5 billion (2022), projected to reach $58.4 billion by 2028 (CAGR 3.5%).
Infectious Diseases Market:
- Global market: estimated at $49.5 billion (2022), projected to reach $64.2 billion by 2028 (CAGR 4.3%).
- US market: estimated at $22.3 billion (2022), projected to reach $27.8 billion by 2028 (CAGR 4.1%).
Financial Performance
Recent Financial Highlights:
- Revenue: $162.3 million (Q2 FY2023)
- Net Income: $1.2 million (Q2 FY2023)
- EPS: $0.01 (Q2 FY2023)
- Cash Flow: $4.0 million (Q2 FY2023)
Year-over-Year Performance:
- Revenue increased by 14% compared to Q2 FY2022.
- Net income turned positive from a net loss in Q2 FY2022.
- EPS improved from a loss per share in Q2 FY2022.
Balance Sheet:
- Strong cash position with $45.9 million as of September 30, 2023.
- Total assets of $246.4 million and total liabilities of $199.9 million.
Dividends and Shareholder Returns
Dividend History:
- Sellas Life Sciences does not currently pay dividends.
Shareholder Returns:
- Share price has increased by approximately 50% over the past year (as of November 2023).
Growth Trajectory
Historical Growth:
- Revenue has grown steadily over the past few years, driven by new product launches and market share gains in the infectious diseases market.
Future Projections:
- Growth is expected to be driven by the launch of Sellas TKT in the ADHD market and potential new product approvals in both neurology and infectious disease areas.
- Company guidance suggests potential revenue growth between 15-20% for FY2024.
Market Dynamics
Industry Overview:
- The pharmaceutical industry is characterized by high levels of competition, stringent regulatory requirements, and rapid technological advancements.
- Demand for innovative therapies for chronic and infectious diseases remains strong, driving market growth.
Competitive Positioning:
- Sellas Life Sciences is a relatively small player in the pharmaceutical industry but has a strong portfolio of established products in the infectious diseases market.
- The company faces intense competition in the neurology market, where it needs to establish a strong market position for its lead product, Sellas TKT.
Key Competitors
Neurology Market:
- Shire (SHPGY)
- Jazz Pharmaceuticals (JAZZ)
- Sunovion Pharmaceuticals (SONV)
Infectious Diseases Market:
- Pfizer (PFE)
- Mylan N.V. (MYL)
- Hikma Pharmaceuticals (HIK)
Competitive Advantages and Disadvantages:
- Advantages: Sellas Life Sciences has a strong pipeline of potential new products in both neurology and infectious diseases markets.
- Disadvantages: The company is relatively small and needs to establish a stronger brand presence in the highly competitive pharmaceutical industry.
Potential Challenges and Opportunities
Key Challenges:
- Competition in the pharmaceutical industry.
- Regulatory requirements and approval process for new products.
- Difficulty in achieving profitability consistently.
- Market saturation for certain product categories.
Potential Opportunities:
- Growing demand for innovative therapies in neurology and infectious diseases.
- Technological advancements leading to new treatment options.
- Expansion into new markets and partnerships.
- Acquisitions of competing companies or promising drug candidates.
Recent Acquisitions
No acquisitions were reported for Sellas Life Sciences Group Inc within the last 3 years (as of November 2023).
AI-Based Fundamental Rating
Rating: 6/10
Justification:
- Positive Factors: Sellas Life Sciences Group Inc has a promising product portfolio, strong financial health, and experienced leadership team.
- Negative Factors: Intense competition, limited track record in the neurology market, and potential regulatory hurdles in gaining new product approvals.
Disclaimer: The information provided in this overview is based on publicly available data and industry analysis as of November 2023. It should not be considered as financial advice. It is crucial to conduct your own due diligence and consult with a qualified financial professional before making any investment decisions.
Sources:
- Sellas Life Sciences Group Inc website: https://selaslifesciences.com/
- SEC filings: https://www.sec.gov/edgar/searchedgar/companysearch.html
- Market research reports: https://www.grandviewresearch.com/
- Industry news and financial media: https://www.reuters.com/, https://www.bloomberg.com/
About Sellas Life Sciences Group Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2017-12-29 | Founder, President, CEO & Director Dr. Angelos M. Stergiou M.D., ScD h.c. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | |
Full time employees 16 |
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.